Cargando…

Anti-angiogenic therapy for ovarian cancer

Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	García García, Yolanda, Marín Alcalá, Maria, Martínez Vila, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573465/ https://www.ncbi.nlm.nih.gov/pubmed/33240446 http://dx.doi.org/10.1016/j.ejcsup.2020.02.003

Ejemplares similares

Anti-angiogenic therapy in ovarian cancer: current situation & prospects
por: Liu, Yinping, et al.
Publicado: (2021)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
por: Mei, Chao, et al.
Publicado: (2023)

The promise of anti-angiogenic cancer therapy
por: Oehler, M K, et al.
Publicado: (2000)

Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013)

Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma
por: Seki, Toshiyuki, et al.
Publicado: (2021)

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
por: Olejarz, Wioletta, et al.
Publicado: (2020)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

Recent Advances in Anti-Angiogenic Therapy of Cancer
por: Samant, Rajeev S., et al.
Publicado: (2011)

Future options of anti-angiogenic cancer therapy
por: Cao, Yihai
Publicado: (2016)

Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
por: Nienhüser, Henrik, et al.
Publicado: (2017)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021)

Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer
por: Loizzi, Vera, et al.
Publicado: (2017)

Anti-angiogenic therapies for advanced esophago-gastric cancer
por: Fontana, Elisa, et al.
Publicado: (2014)

Anti-angiogenic therapies in the management of glioblastoma
por: Schulte, Jessica D., et al.
Publicado: (2021)

Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
por: Comunanza, Valentina, et al.
Publicado: (2017)

Tumor angiogenesis and anti-angiogenic gene therapy for cancer
por: Li, Tinglu, et al.
Publicado: (2018)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
por: Itatani, Yoshiro, et al.
Publicado: (2018)

Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy
por: Zheng, Tianying, et al.
Publicado: (2017)

Tumor T(1) Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model
por: Ravoori, Murali K., et al.
Publicado: (2015)

Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy
por: Fujii, Hiroko, et al.
Publicado: (2013)

Anti-angiogenic peptides application in cancer therapy; a review
por: Shoari, Alireza, et al.
Publicado: (2021)

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
por: Abdalla, Ahmed M.E., et al.
Publicado: (2018)

Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
por: Saoudi González, Nadia, et al.
Publicado: (2022)

Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
por: Pircher, Andreas, et al.
Publicado: (2011)

Trends and Challenges in Tumor Anti-Angiogenic Therapies
por: Jászai, József, et al.
Publicado: (2019)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

Potential of peptide‐engineered exosomes with overexpressed miR‐92b‐3p in anti‐angiogenic therapy of ovarian cancer
por: Wang, Jiaying, et al.
Publicado: (2021)

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
por: Xu, Donghan, et al.
Publicado: (2023)

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more
por: Wang, Zhi-Bin, et al.
Publicado: (2023)

Anti-Angiogenic and Anti-Proliferative Graphene Oxide Nanosheets for Tumor Cell Therapy
por: Verde, Valeria, et al.
Publicado: (2020)

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Tian, Wentao, et al.
Publicado: (2020)

Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer
por: Zeng, Ye, et al.
Publicado: (2020)

Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
por: Lupo, Gabriella, et al.
Publicado: (2017)

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
por: Kong, Deok-Hoon, et al.
Publicado: (2017)

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential
por: Lahooti, Behnaz, et al.
Publicado: (2021)

Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer
por: Giri, Shailendra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_727s21k401phaeifk5g1ds7mpc